To further improve clinical activities in psychiatry by early diagnosis and early intervention with novel mechanism‐guided treatments, there is a great need for biomarkers that reflect ‘trait’ and ‘state’ in… Click to show full abstract
To further improve clinical activities in psychiatry by early diagnosis and early intervention with novel mechanism‐guided treatments, there is a great need for biomarkers that reflect ‘trait’ and ‘state’ in major mental disorders. Stable trait biomarkers would allow early diagnosis, prognosis, and hopefully early intervention in these disorders, while dynamic state markers that reflect symptomatic changes would help to develop treatments that target these molecular mechanisms. However, in the search for such biomarkers, and eventually translating them to the clinic and industry, challenges currently exist at multiple levels, from basic scientific understanding, patient sample collection, and sample and data management, to bridging the gap between basic and clinical research and industry. To address these challenges, we propose an infrastructure that emphasizes: (i) a research and educational framework to facilitate translation between basic neuroscience, clinical research, and industry; (ii) patient recruitment and collection of disease‐relevant samples to study trait and state biomarkers; and (iii) a comprehensive database to integrate patient and sample information with biological and clinical data. We believe that such an approach would bolster: research into the biological mechanisms of psychiatric disorders; and collaboration among the laboratory, clinic, and industry to translate these findings into successful treatments.
               
Click one of the above tabs to view related content.